Presentations at SABCS 2013
The following LACOG projects were be presented at the San Antonio Breast Cancer Symposium (SABCS) December 2013.
[P4-12-26] A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)
[P1-09-06] Breast cancer in the Pan-American region: Inequities in incidence and mortality rates according to the human development index
[OT2-6-11] PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13)